Targeted activation of human vγ9vδ2-T cells controls epstein-barr virus-induced B cell lymphoproliferative disease

Cancer Cell

Volumn 26, Issue 4, 2014, Pages 565-576

  Xiang, Zheng ^a   Liu, Yinping ^a   Zheng, Jian ^a   Liu, Ming ^b   Lv, Aizhen ^a   Gao, Yulong ^a   Hu, Huaidong ^c   Lam, Kowk Tai ^a   Chan, GodfreyChi Fung ^a   Yang, Yuanzhong ^d   Chen, Honglin ^a   Tsao, GeorgeSai Wah ^a   Bonneville, Marc ^e,f,g   Lau, Yu Lung ^a   Tu, Wenwei ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

^c THE SECOND AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

^d SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^e UNIVERSITÉ DE NANTES   (France)

^f Team 12   (France)

^g Institut Merieux   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD69 ANTIGEN; CONCANAMYCIN A; CXCL9 CHEMOKINE; DEATH RECEPTOR 4; FAS ANTIGEN; FAS LIGAND; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE COLONY STIMULATING FACTOR; GRANZYME B; HLA A ANTIGEN; HLA B ANTIGEN; INTERLEUKIN 8; LATENT MEMBRANE PROTEIN 1; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; NATURAL KILLER CELL RECEPTOR NKG2D; PAMIDRONIC ACID; PERFORIN; RANTES; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIVIRAL ACTIVITY; ARTICLE; CELL EXPANSION; CONTROLLED STUDY; DRUG CYTOTOXICITY; EPSTEIN BARR VIRUS INDUCED B CELL LYMPHOPROLIFERATIVE DISEASE; EPSTEIN BARR VIRUS INFECTION; EXOCYTOSIS; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFECTION PREVENTION; INOCULATION; LYMPHOBLASTOID CELL LINE; LYMPHOPROLIFERATIVE DISEASE; MALE; MOUSE; NONHUMAN; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE RECEPTOR GENE; UPREGULATION; VGAMMA9VDELTA 2 T CELL; VIROGENESIS; ANIMAL; B LYMPHOCYTE; EPSTEIN BARR VIRUS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; PATHOPHYSIOLOGY; PHYSIOLOGY;

HUMAN HERPESVIRUS 4;

ANIMALS; B-LYMPHOCYTES; HERPESVIRUS 4, HUMAN; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOPROLIFERATIVE DISORDERS; MICE; T-LYMPHOCYTES;

EID: 84907996988     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2014.07.026     Document Type: Article

References (40)

1. Alexander A.A., Maniar A., Cummings J.S., Hebbeler A.M., Schulze D.H., Gastman B.R., Pauza C.D., Strome S.E., Chapoval A.I. Isopentenyl pyrophosphate-activated CD56+ gammadelta T lymphocytes display potent antitumor activity toward human squamous cell carcinoma. Clin. Cancer Res. 2008, 14:4232-4240.
2. Beetz S., Wesch D., Marischen L., Welte S., Oberg H.H., Kabelitz D. Innate immune functions of human gammadelta Tcells. Immunobiology 2008, 213:173-182.
3. Bonneville M., Scotet E. Human Vgamma9Vdelta2 Tcells: promising new leads for immunotherapy of infections and tumors. Curr. Opin. Immunol. 2006, 18:539-546.
4. Bonneville M., O'Brien R.L., Born W.K. Gammadelta Tcell effector functions: a blend of innate programming and acquired plasticity. Nat. Rev. Immunol. 2010, 10:467-478.
5. Born W.K., Reardon C.L., O'Brien R.L. The function of gammadelta Tcells in innate immunity. Curr. Opin. Immunol. 2006, 18:31-38.
6. Carding S.R., Egan P.J. Gammadelta Tcells: functional plasticity and heterogeneity. Nat. Rev. Immunol. 2002, 2:336-345.
7. Cohen J.I. Epstein-Barr virus infection. N.Engl. J. Med. 2000, 343:481-492.
8. Das H., Wang L., Kamath A., Bukowski J.F. Vgamma2Vdelta2 T-cell receptor-mediated recognition of aminobisphosphonates. Blood 2001, 98:1616-1618.
9. Fournié J.J., Sicard H., Poupot M., Bezombes C., Blanc A., Romagné F., Ysebaert L., Laurent G. What lessons can be learned from γδ Tcell-based cancer immunotherapy trials?. Cell. Mol. Immunol. 2013, 10:35-41.
10. Funakoshi S., Longo D.L., Beckwith M., Conley D.K., Tsarfaty G., Tsarfaty I., Armitage R.J., Fanslow W.C., Spriggs M.K., Murphy W.J. Inhibition of human B-cell lymphoma growth by CD40 stimulation. Blood 1994, 83:2787-2794.
11. Heslop H.E., Slobod K.S., Pule M.A., Hale G.A., Rousseau A., Smith C.A., Bollard C.M., Liu H., Wu M.F., Rochester R.J., et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 2010, 115:925-935.
12. Kabelitz D., Wesch D., He W. Perspectives of gammadelta Tcells in tumor immunology. Cancer Res. 2007, 67:5-8.
13. Kanakry J.A., Ambinder R.F. EBV-related lymphomas: new approaches to treatment. Curr. Treat. Options Oncol. 2013, 14:224-236.
14. Khanna R., Bell S., Sherritt M., Galbraith A., Burrows S.R., Rafter L., Clarke B., Slaughter R., Falk M.C., Douglass J., et al. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic Tcells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proc. Natl. Acad. Sci. USA 1999, 96:10391-10396.
15. Khanna R., Moss D., Gandhi M. Technology insight: Applications of emerging immunotherapeutic strategies for Epstein-Barr virus-associated malignancies. Nat. Clin. Pract. Oncol. 2005, 2:138-149.
16. Kong Y., Cao W., Xi X., Ma C., Cui L., He W. The NKG2D ligand ULBP4 binds to TCRgamma9/delta2 and induces cytotoxicity to tumor cells through both TCRgammadelta and NKG2D. Blood 2009, 114:310-317.
17. Kotsiopriftis M., Tanner J.E., Alfieri C. Heat shock protein 90 expression in Epstein-Barr virus-infected B cells promotes gammadelta T-cell proliferation invitro. J.Virol. 2005, 79:7255-7261.
18. Kunzmann V., Bauer E., Wilhelm M. Gamma/delta T-cell stimulation by pamidronate. N.Engl. J. Med. 1999, 340:737-738.
19. Lacerda J.F., Ladanyi M., Louie D.C., Fernandez J.M., Papadopoulos E.B., O'Reilly R.J. Human Epstein-Barr virus (EBV)-specific cytotoxic Tlymphocytes home preferentially to and induce selective regressions of autologous EBV-induced B cell lymphoproliferations in xenografted C.B-17 scid/scid mice. J.Exp. Med. 1996, 183:1215-1228.
20. Leen A.M., Rooney C.M., Foster A.E. Improving Tcell therapy for cancer. Annu. Rev. Immunol. 2007, 25:243-265.
21. Li H., Xiang Z., Feng T., Li J., Liu Y., Fan Y., Lu Q., Yin Z., Yu M., Shen C., Tu W. Human Vγ9Vδ2-T cells efficiently kill influenza virus-infected lung alveolar epithelial cells. Cell. Mol. Immunol. 2013, 10:159-164.
22. Lim W.H., Kireta S., Russ G.R., Coates P.T. Human plasmacytoid dendritic cells regulate immune responses to Epstein-Barr virus (EBV) infection and delay EBV-related mortality in humanized NOD-SCID mice. Blood 2007, 109:1043-1050.
23. Long H.M., Taylor G.S., Rickinson A.B. Immune defence against EBV and EBV-associated disease. Curr. Opin. Immunol. 2011, 23:258-264.
24. Louis C.U., Straathof K., Bollard C.M., Gerken C., Huls M.H., Gresik M.V., Wu M.F., Weiss H.L., Gee A.P., Brenner M.K., et al. Enhancing the invivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients. Blood 2009, 113:2442-2450.
25. Ma S.D., Hegde S., Young K.H., Sullivan R., Rajesh D., Zhou Y., Jankowska-Gan E., Burlingham W.J., Sun X., Gulley M.L., et al. A new model of Epstein-Barr virus infection reveals an important role for early lytic viral protein expression in the development of lymphomas. J.Virol. 2011, 85:165-177.
26. Orsini D.L., van Gils M., Kooy Y.M., Struyk L., Klein G., van den Elsen P., Koning F. Functional and molecular characterization of B cell-responsive V delta 1+ gamma delta Tcells. Eur. J. Immunol. 1994, 24:3199-3204.
27. Puan K.J., Jin C., Wang H., Sarikonda G., Raker A.M., Lee H.K., Samuelson M.I., Märker-Hermann E., Pasa-Tolic L., Nieves E., et al. Preferential recognition of a microbial metabolite by human Vgamma2Vdelta2 Tcells. Int. Immunol. 2007, 19:657-673.
28. Qin G., Mao H., Zheng J., Sia S.F., Liu Y., Chan P.L., Lam K.T., Peiris J.S., Lau Y.L., Tu W. Phosphoantigen-expanded human gammadelta Tcells display potent cytotoxicity against monocyte-derived macrophages infected with human and avian influenza viruses. J.Infect. Dis. 2009, 200:858-865.
29. Qin G., Liu Y., Zheng J., Ng I.H., Xiang Z., Lam K.T., Mao H., Li H., Peiris J.S., Lau Y.L., Tu W. Type 1 responses of human Vγ9Vδ2 Tcells to influenza A viruses. J.Virol. 2011, 85:10109-10116.
30. Qin G., Liu Y., Zheng J., Xiang Z., Ng I.H., Malik Peiris J.S., Lau Y.L., Tu W. Phenotypic and functional characterization of human γδ T-cell subsets in response to influenza A viruses. J.Infect. Dis. 2012, 205:1646-1653.
31. Rooney C.M., Smith C.A., Ng C.Y., Loftin S., Li C., Krance R.A., Brenner M.K., Heslop H.E. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 1995, 345:9-13.
32. Shapiro R.S., McClain K., Frizzera G., Gajl-Peczalska K.J., Kersey J.H., Blazar B.R., Arthur D.C., Patton D.F., Greenberg J.S., Burke B., et al. Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood 1988, 71:1234-1243.
33. Sicard H., Ingoure S., Luciani B., Serraz C., Fournié J.J., Bonneville M., Tiollier J., Romagné F. Invivo immunomanipulation of V gamma 9V delta 2 Tcells with a synthetic phosphoantigen in a preclinical nonhuman primate model. J.Immunol. 2005, 175:5471-5480.
34. Speck P., Longnecker R. Epstein-Barr virus (EBV) infection visualized by EGFP expression demonstrates dependence on known mediators of EBV entry. Arch. Virol. 1999, 144:1123-1137.
35. Strowig T., Brilot F., Arrey F., Bougras G., Thomas D., Muller W.A., Münz C. Tonsilar NK cells restrict B cell transformation by the Epstein-Barr virus via IFN-gamma. PLoS Pathog. 2008, 4:e27.
36. Tu W., Zheng J., Liu Y., Sia S.F., Liu M., Qin G., Ng I.H., Xiang Z., Lam K.T., Peiris J.S., Lau Y.L. The aminobisphosphonate pamidronate controls influenza pathogenesis by expanding a gammadelta Tcell population in humanized mice. J.Exp. Med. 2011, 208:1511-1522.
37. Tzartos J.S., Khan G., Vossenkamper A., Cruz-Sadaba M., Lonardi S., Sefia E., Meager A., Elia A., Middeldorp J.M., Clemens M., et al. Association of innate immune activation with latent Epstein-Barr virus in active MS lesions. Neurology 2012, 78:15-23.
38. Wagner-Johnston N.D., Ambinder R.F. Epstein-Barr virus-related lymphoproliferative disorders. Curr Hematol Malig Rep 2007, 2:249-254.
39. Zheng J., Liu Y., Lau Y.L., Tu W. γδ-T cells: an unpolished sword in human anti-infection immunity. Cell. Mol. Immunol. 2013, 10:50-57.
40. Zheng J., Liu Y., Liu M., Xiang Z., Lam K.T., Lewis D.B., Lau Y.L., Tu W. Human CD8+ regulatory Tcells inhibit GVHD and preserve general immunity in humanized mice. Sci Transl Med 2013, 5:168-169.